Browse by author
Lookup NU author(s): Professor Ann DalyORCiD
This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).
© 2023 by the author.There has been widespread implementation of pharmacogenomic testing to inform drug prescribing in medical specialties such as oncology and cardiology. Progress in using pharmacogenomic tests when prescribing antimicrobials has been more limited, though a relatively large number of pharmacogenomic studies on aspects such as idiosyncratic adverse drug reactions have now been performed for this drug class. Currently, there are recommendations in place from either National Regulatory Agencies and/or specialist Pharmacogenomics Advisory Groups concerning genotyping for specific variants in MT-RNR1 and CYP2C19 before prescribing aminoglycosides and voriconazole, respectively. Numerous additional pharmacogenomic associations have been reported concerning antimicrobial-related idiosyncratic adverse drug reactions, particularly involving specific HLA alleles, but, to date, the cost-effectiveness of genotyping prior to prescription has not been confirmed. Polygenic risk score determination has been investigated to a more limited extent but currently suffers from important limitations. Despite limited progress to date, the future widespread adoption of preemptive genotyping and genome sequencing may provide pharmacogenomic data to prescribers that can be used to inform prescribing and increase the safe use of antimicrobials.
Author(s): Daly AK
Publication type: Article
Publication status: Published
Journal: Antibiotics
Year: 2023
Volume: 12
Issue: 3
Print publication date: 01/03/2023
Online publication date: 21/02/2023
Acceptance date: 20/02/2023
Date deposited: 05/05/2023
ISSN (electronic): 2079-6382
Publisher: MDPI
URL: https://doi.org/10.3390/antibiotics12030425
DOI: 10.3390/antibiotics12030425
Altmetrics provided by Altmetric
